Ann Conkle
Mar 26, 2012

Promising results for new cholesterol control mechanism

Data from a phase 2 clinical trial show that a treatment targeting the PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody could be a new treatment for high cholesterol. Over an 8 to 12 week period, the new drug, developed by Sanofi and Regeneron Pharmaceuticals, reduced mean low-density lipoprotein-cholesterol (LDL, or ‘bad’ cholesterol) by 40 to 72 percent in patients with elevated LDL. PCSK9 is an example of how the study of genetics can identify new targets for therapies -- its role in lipid metabolism was discovered a few years ago in population studies. “Genetic data have shown that patients with natural loss-of-function mutations in PCSK9 have significantly lower LDL-C and a lower risk of coronary heart disease,” said Dr. Elias Zerhouni, President, Global Research & Development, Sanofi. “Based on this finding and the results of our Phase 2 trials, Sanofi and Regeneron plan to initiate the … Phase 3 program in the second quarter.”

0 Comments
Related Articles
Ann Conkle
Feb 21, 2012
Berkeley Lab researchers find new evidence for how good cholesterol turns bad
Researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab) have found new evidence to explain how cholesteryl ester transfer protein... Read More
Ann Conkle
Feb 24, 2012
Statins linked with lower depression risk in heart patients
Patients with heart disease who took cholesterol-lowering statins were less likely to develop depression than those who did not, in... Read More
Kristin Wall
Mar 19, 2012
New weight loss drug stops fat from forming
We’re all familiar with the so-called weight loss drugs advertised on TV that claim unbelievable results, show before and after... Read More